Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 24;17(6):752.
doi: 10.3390/v17060752.

Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease

Affiliations
Review

Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease

Kriti Soni et al. Viruses. .

Abstract

Cytomegalovirus (CMV) colitis, a complication in patients with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), is a significant diagnostic and therapeutic challenge due to its overlap with IBD flares. CMV reactivation in IBD is driven by chronic inflammation, compromised immune function, and use of immunosuppressive agents like corticosteroids. Risk factors include older age, pancolitis, and severe disease. Diagnosis hinges on endoscopy and histology, with tissue biopsy and immunohistochemistry as the gold standard. Quantitative tissue PCR may aid in differentiating latent from active infection. CMV colitis exacerbates IBD symptoms, prolongs hospitalization, and increases colectomy rates. Antiviral therapy, primarily ganciclovir, improves outcomes in patients with corticosteroid-refractory UC. Treatment focuses on tapering corticosteroids, optimizing biologic therapies such as infliximab, and a careful application of antivirals tailored to disease severity and viral load. Further research is needed to refine diagnostic thresholds and treatment strategies to mitigate CMV's impact on IBD prognosis. Early identification and individualized management are critical to improving clinical outcomes and reducing morbidity.

Keywords: colitis; cytomegalovirus; inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Colonoscopy image showing mucosal ulceration of the distal rectum in CMV colitis in an immunocompetent patient [36].
Figure 2
Figure 2
CMV-infected (a) mesenchymal cells from colonic tissue; (b) endothelial cells from colonic tissue. These CMV-infected cells have large ovoid nuclei with basophilic intranuclear inclusions (Cowdry bodies) surrounded by a clear halo (arrows) [37].
Figure 3
Figure 3
H&E stain of rectal biopsy, showing a large nucleus (arrow) with a smudged, eosinophilic chromatin pattern consistent with cytomegalovirus colitis [36].
Figure 4
Figure 4
Diagnostic approach for CMV colitis.
Figure 5
Figure 5
Treatment approach for CMV colitis.

References

    1. Flanders W.D., Lally C., Dilley A., Diaz-Decaro J. Estimated cytomegalovirus seroprevalence in the general population of the United States and Canada. J. Med. Virol. 2024;96:e29525. doi: 10.1002/jmv.29525. - DOI - PubMed
    1. Gandhi M.K., Khanna R. Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis. 2004;4:725–738. doi: 10.1016/S1473-3099(04)01202-2. - DOI - PubMed
    1. Dioverti M.V., Razonable R.R. Cytomegalovirus. Microbiol. Spectr. 2016;4:97–125. doi: 10.1128/microbiolspec.DMIH2-0022-2015. - DOI - PubMed
    1. Ljungman P., Chemaly R.F., Khawaya F., Alain S., Avery R., Badshah C., Boeckh M., Fournier M., Hodowanec A., Komatsu T., et al. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum. Clin. Infect. Dis. 2024;79:787–794. doi: 10.1093/cid/ciae321. - DOI - PMC - PubMed
    1. Kandiel A., Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am. J. Gastroenterol. 2006;101:2857–2865. doi: 10.1111/j.1572-0241.2006.00869.x. - DOI - PubMed

MeSH terms

Substances